NCT06792968 - Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 30, 2025

Primary Completion Date

April 6, 2025

Study Completion Date

April 8, 2025

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets

1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated table

DRUG

Synjardy 5 mg/1000 mg film-coated tablets

1 tablet of Empagliflozin+Metformin 5 mg/1000 mg filmcoated tablets

Trial Locations (1)

"State Budgetary Institution of Healthcare of Yaroslavl region Yaroslavl Regional Clinical Narcological Hospital", Yaroslavl